Eli Lilly Stock Has The Technicals: Will Q1 Earnings Deliver Fundamentals?

Core Viewpoint - Eli Lilly And Co is set to report its first-quarter earnings, with Wall Street expecting an EPS of $3.05 and revenues of $12.67 billion, indicating strong market anticipation for the company's performance [1]. Group 1: Stock Performance - Eli Lilly's stock has increased by 14.35% over the past year and 14.79% year-to-date, reflecting positive investor sentiment [1]. - The current stock price is $896.20, which is significantly above key moving averages, indicating strong upward momentum [2]. Group 2: Technical Analysis - The stock is trading above its five-day, 20-day, and 50-day exponential moving averages, signaling sustained buying interest and bullish momentum [2]. - Eli Lilly's stock also exceeds its eight-day simple moving average of $859.74, 20-day SMA of $798.34, and 50-day SMA of $834.64, all of which are bullish indicators [3]. - The stock remains above its 200-day SMA of $844.59, a long-term bullish indicator closely monitored by institutional investors [3]. - The Moving Average Convergence Divergence (MACD) reading is at 18.97, reinforcing the bullish momentum with a positive divergence [3]. - The Relative Strength Index (RSI) is at 64.49, suggesting that the stock is not yet overbought and has potential for further gains [4]. Group 3: Analyst Ratings - The consensus analyst rating for Eli Lilly stock is currently a Buy, with a price target of $945.70 [5]. - Recent analyst ratings from HSBC, Cantor Fitzgerald, and Guggenheim suggest a 2.95% downside, with an average price target of $867.67 [5]. - At the time of publication, Eli Lilly stock was trading at $895.25 [5].